Response to Mazzaschi and Buti

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)


We thank Mazzaschi and Buti for their comments on the article entitled “Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor (PPI) Treatment: Pooled Analysis of Five Randomized Control Trials.”1 We read,with interest, the proposition for future research on the impacts of concomitantly dosed corticosteroids and probiotics on the efficacy of atezolizumab-based regimens in NSCLC, which has merit. However, prestudy, it was determined that the evaluation of subgroups within subgroups (i.e., corticosteroids users within the PPI users, who are randomized atezolizumab) would have limited validity on interaction analysis.
Original languageEnglish
Pages (from-to)e90
Number of pages1
JournalJournal of Thoracic Oncology
Issue number10
Publication statusPublished - Oct 2022


  • Antibiotics
  • Atezolizumab
  • Gut dysbiosis
  • Non–small cell lung cancer
  • Proton pump inhibitors
  • Survival
  • Corticosteroids


Dive into the research topics of 'Response to Mazzaschi and Buti'. Together they form a unique fingerprint.

Cite this